# Efficacy and Safety of Venetoclax Combined With BEAM Pretreatment in Autologous Transplantation for DLBCL

> **NCT05863845** · NA · UNKNOWN · sponsor: **Ruijin Hospital** · enrollment: 52 (estimated)

## Conditions studied

- Diffuse Large B Cell Lymphoma

## Interventions

- **DRUG:** Venetoclax
- **DRUG:** Carmustine
- **DRUG:** Cytarabine
- **DRUG:** Etoposide
- **DRUG:** Melphalan
- **PROCEDURE:** Hematopoietic Cell Transplantation

## Key facts

- **NCT ID:** NCT05863845
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-06-01
- **Primary completion:** 2024-11-30
- **Final completion:** 2025-11-30
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2023-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05863845

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05863845, "Efficacy and Safety of Venetoclax Combined With BEAM Pretreatment in Autologous Transplantation for DLBCL". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05863845. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*